NKG2D/CD28 chimeric receptor boosts cytotoxicity and durability of CAR-T cells for solid and hematological tumors
The combination of CAR and NKG2D/CD28 offers a potent strategy to enhance the cytotoxicity and durability of CAR-T cells. This approach is promising for improving therapeutic outcomes in solid and hematological tumors and preventing recurrence in tumors with low target antigen density.
Authors
- Zhihua Tian (ORCID: https://orcid.org/0000-0003-2226-3947)
- Jiaxin Cindy Tu (ORCID: https://orcid.org/0000-0003-1982-9890)
- Zheming Lu (ORCID: https://orcid.org/0000-0003-3775-9435)
- Shance Li
- Chaoting Zhang
- Kang Sun (ORCID: https://orcid.org/0000-0003-2727-141X)
- Xia Teng
- Ting Liu (ORCID: https://orcid.org/0000-0003-1816-5551)
- Guanyu Zhang (ORCID: https://orcid.org/0000-0003-0965-218X)
- Huimin Xie (ORCID: https://orcid.org/0000-0002-0382-9653)
- Huirong Ding
- Yuge Zhu
Institutions
- Peking University (CN)
- Peking University Cancer Hospital (CN)
Publication Details
- Journal
- Experimental Hematology and Oncology
- Published
- 2025-04-03
- DOI
- https://doi.org/10.1186/s40164-025-00646-3
- Citations
- 4
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 4.18
Funders
- National Natural Science Foundation of China
- National Science and Technology Major Project
- Beijing Nova Program